Long-term Safety and Efficacy of Once-Weekly Lonapegsomatropin in Adults With Growth Hormone Deficiency: Results From a 52-Week Open-Label Extension Trial. uri icon

authors

  • Biller, Beverly M K
  • Irina Bancos, MD
  • Schilbach, Katharina
  • Iklé, Jennifer M
  • Komirenko, Allison S
  • Zhong, Wei
  • Hu, Yetao
  • Domrzalski, Laurie
  • Shu, Aimee D
  • Yuen, Kevin C J
  • Gilis-Januszewska, Aleksandra
  • Doknic, Mirjana
  • Picó, Antonio Miguel
  • Fleseriu, Maria
  • Raverot, Gerald
  • Isidori, Andrea M
  • Garcia, Jose M
  • Silverstein, Julie M

publication date

  • October 9, 2026